1. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain 
William D. Schlaff, M.D., Sandra Ann Carson, M.D., Anthony Luciano, M.D., Doug Ross, M.D., Agneta Bergqvist, M.D. 
Fertility and Sterility 
Volume 85, Issue 2, Pages (February 2006)
DOI: /j.fertnstert
Copyright © 2006 American Society for Reproductive Medicine Terms and Conditions

2. FIGURE 1
Mean pain assessment by visit for endometrial signs and symptoms based on the modified Biberoglu and Behrman (B&B) symptom scale, where 0 = absent/none, 1 = mild, 2 = moderate, and 3 = severe. Data are presented for the intent-to-treat population at baseline (blue bars), at end of treatment (month 6; red bars), and at 12 months after treatment (month 18; yellow bars). (A) Results for patients in the DMPA-SC 104 group. (B) Results for patients in the leuprolide group.
Schlaff. DMPA-SC 104 reduces endometriosis-related pain. Fertil Steril 2006.
Fertility and Sterility  , DOI: ( /j.fertnstert )
Copyright © 2006 American Society for Reproductive Medicine Terms and Conditions

3. FIGURE 2
Percentages of patients treated with DMPA-SC 104 (blue bars) or leuprolide (red bars), showing improvement in five individual signs and symptoms of endometriosis compared with baseline when observed case analysis was used for the intent-to-treat population. Improvement was defined as a decrease of at least one point in the score relative to baseline when using the modified Biberoglu and Behrman scale. (A) At end of treatment (month 6). (B) After 12 months of follow-up (month 18). aTreatments not equivalent.
Schlaff. DMPA-SC 104 reduces endometriosis-related pain. Fertil Steril 2006.
Fertility and Sterility  , DOI: ( /j.fertnstert )
Copyright © 2006 American Society for Reproductive Medicine Terms and Conditions

4. FIGURE 3
Median percentage changes in BMD after 6 months of treatment with DMPA-SC 104 (red bars) or leuprolide (yellow bars) and after 12 months of posttreatment follow-up (month 18) compared with baseline for the intent-to-treat population. n = total reported (DMPA-SC 104 group/leuprolide group). aStatistically significant within-treatment group differences (Wilcoxon’s signed rank test, significance defined at P≤.05). bStatistically significantly greater decrease observed in the leuprolide group vs. DMPA-SC 104 group (Kruskal-Wallis test, significance defined at P≤.05).
Schlaff. DMPA-SC 104 reduces endometriosis-related pain. Fertil Steril 2006.
Fertility and Sterility  , DOI: ( /j.fertnstert )
Copyright © 2006 American Society for Reproductive Medicine Terms and Conditions

5. FIGURE 4
Median changes from baseline in Kupperman Index during 6 months of treatment with DMPA-SC 104 (red line) or leuprolide (yellow line), where increasing scores indicate an increase in hypoestrogenic symptoms (intent to treat population). P values for between-group differences (Kruskal-Wallis test) were ≤ .011 for all time points: aP=.011; bP<.001; cP=.001; and dP=.002.
Schlaff. DMPA-SC 104 reduces endometriosis-related pain. Fertil Steril 2006.
Fertility and Sterility  , DOI: ( /j.fertnstert )
Copyright © 2006 American Society for Reproductive Medicine Terms and Conditions

6. FIGURE 5
Impact of treatment on QOL (intent to treat population): mean scores on four prespecified and two additional EHP-30 scales at baseline (blue bars), month 6 (end of treatment; red bars), and at the 12-month follow-up (yellow bars). Lower scores indicate improvement on each scale. P values for within-group differences from baseline (t-test): aP≤.001; bP=.008. (A) Results for patients in the DMPA-SC 104 group. (B) Results for patients in the leuprolide group.
Schlaff. DMPA-SC 104 reduces endometriosis-related pain. Fertil Steril 2006.
Fertility and Sterility  , DOI: ( /j.fertnstert )
Copyright © 2006 American Society for Reproductive Medicine Terms and Conditions